The Shareholders Foundation announces that a deadline is coming up on March 13, 2017 in the lawsuit filed for certain investors in NASDAQ:SGEN shares against Seattle Genetics, Inc over alleged securities laws violations.
Investors who purchased shares of Seattle Genetics, Inc. (NASDAQ:SGEN) have certain options and there are strict and short deadlines running. Deadline: March 13, 2017. NASDAQ:SGEN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The plaintiff alleges on behalf of certain purchasers of Seattle Genetics, Inc. (NASDAQ:SGEN) that the Defendants made false and/or misleading statements and/or failed to disclose that vadastuximab talirine presents a significant risk of fatal hepatotoxicity, that as such, Seattle Genetics had overstated the viability of vadastuximab talirine as an acute myeloid leukemia (AML) treatment, and that as a result of the foregoing, Seattle Genetics’ public statements were materially false and misleading at all relevant times.
On December 27, 2016, Seattle Genetics, Inc. (NASDAQ:SGEN) announced that it has received notice from the U.S. Food and Drug Administration (“FDA“) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML). Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) declined on December 27, 2016 to as low as $51.63 per share.
On March 10, 2016, NASDAQ:SGEN shares closed at $67.96 per share.
Those who purchased NASDAQ:SGEN shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com